$AKTX “We remain focused on our mission of addressing severe inflammatory diseases with significant unmet medical need.
We are pleased that our company is now in the process of planning or undertaking pivotal trials in both BP and HSCT-TMA as well as
progressing next clinical steps for studies in
atopic keratoconjunctivitis (AKC)
and COVID-19 pneumonia,”
said Clive Richardson, Chief Executive Officer of Akari Therapeutics.
Severe inflammatory diseases remain an area of high unmet need.
Akari continues to make progress driving its anti-inflammatory programs forward, including the recent announcement of positive topline results
from our Phase II BP study in May.
Market Data 
Markets 
AI
